Expert review: preeclampsia Type I and Type II
- PMID: 37871693
- DOI: 10.1016/j.ajogmf.2023.101203
Expert review: preeclampsia Type I and Type II
Abstract
Pregnancy involves an interplay between maternal and fetal factors affecting changes to maternal anatomy and physiology to support the developing fetus and ensure the well-being of both the mother and offspring. A century of research has provided evidence of the imperative role of the placenta in the development of preeclampsia. Recently, a growing body of evidence has supported the adaptations of the maternal cardiovascular system during normal pregnancy and its maladaptation in preeclampsia. Debate surrounds the roles of the placenta vs the maternal cardiovascular system in the pathophysiology of preeclampsia. We proposed an integrated model of the maternal cardiac-placental-fetal array and the development of preeclampsia, which reconciles the disease phenotypes and their proposed origins, whether placenta-dominant or maternal cardiovascular system-dominant. These phenotypes are sufficiently diverse to define 2 distinct types: preeclampsia Type I and Type II. Type I preeclampsia may present earlier, characterized by placental dysfunction or malperfusion, shallow trophoblast invasion, inadequate spiral artery conversion, profound syncytiotrophoblast stress, elevated soluble fms-like tyrosine kinase-1 levels, reduced placental growth factor levels, high peripheral vascular resistance, and low cardiac output. Type I is more often accompanied by fetal growth restriction, and low placental growth factor levels have a measurable impact on maternal cardiac remodeling and function. Type II preeclampsia typically occurs in the later stages of pregnancy and entails an evolving maternal cardiovascular intolerance to the demands of pregnancy, with a moderately dysfunctional placenta and inadequate blood supply. The soluble fms-like tyrosine kinase-1-placental growth factor ratio may be normal or slightly disturbed, peripheral vascular resistance is low, and cardiac output is high, but these adaptations still fail to meet demand. Emergent placental dysfunction, coupled with an increasing inability to meet demand, more often appears with fetal macrosomia, multiple pregnancies, or prolonged pregnancy. Support for the notion of 2 types of preeclampsia observable on the molecular level is provided by single-cell transcriptomic survey of gene expression patterns across different cell classes. This revealed widespread dysregulation of gene expression across all cell types, and significant imbalance in fms-like tyrosine kinase-1 (FLT1) and placental growth factor, particularly marked in the syncytium of early preeclampsia cases. Classification of preeclampsia into Type I and Type II can inform future research to develop targeted screening, prevention, and treatment approaches.
Keywords: PlGF; cardiac output; decidua; decidual natural killer cells; endoglin; endothelial dysfunction; gestational hypertension; great obstetrical syndromes; maternal cardiovascular adaptation; maternal heart; oxidative stress; peripheral vascular resistance; placenta; placental growth factor; preeclampsia; preeclampsia Type I; preeclampsia Type II; pregnancy complications; pregnancy-trained decidual natural killer cells; primiparity; sFlt-1; soluble fms-like tyrosine kinase-1; spiral artery remodeling; twilight placenta.
Copyright © 2023 Elsevier Inc. All rights reserved.
Similar articles
-
An integrated model of preeclampsia: a multifaceted syndrome of the maternal cardiovascular-placental-fetal array.Am J Obstet Gynecol. 2022 Feb;226(2S):S963-S972. doi: 10.1016/j.ajog.2020.10.023. Epub 2021 Mar 9. Am J Obstet Gynecol. 2022. PMID: 33712272 Review.
-
In vivo uteroplacental release of placental growth factor and soluble Fms-like tyrosine kinase-1 in normal and preeclamptic pregnancies.Am J Obstet Gynecol. 2016 Dec;215(6):782.e1-782.e9. doi: 10.1016/j.ajog.2016.07.056. Epub 2016 Aug 5. Am J Obstet Gynecol. 2016. PMID: 27503620
-
Serum amyloid A1 and pregnancy zone protein in pregnancy complications and correlation with markers of placental dysfunction.Am J Obstet Gynecol MFM. 2023 Jan;5(1):100794. doi: 10.1016/j.ajogmf.2022.100794. Epub 2022 Nov 9. Am J Obstet Gynecol MFM. 2023. PMID: 36334725
-
Toward a new taxonomy of obstetrical disease: improved performance of maternal blood biomarkers for the great obstetrical syndromes when classified according to placental pathology.Am J Obstet Gynecol. 2022 Oct;227(4):615.e1-615.e25. doi: 10.1016/j.ajog.2022.04.015. Epub 2022 Sep 3. Am J Obstet Gynecol. 2022. PMID: 36180175 Free PMC article.
-
Preeclampsia and eclampsia: the conceptual evolution of a syndrome.Am J Obstet Gynecol. 2022 Feb;226(2S):S786-S803. doi: 10.1016/j.ajog.2021.12.001. Am J Obstet Gynecol. 2022. PMID: 35177220 Free PMC article. Review.
Cited by
-
Overexpression of Human sFLT1 in the Spongiotrophoblast Is Sufficient to Induce Placental Dysfunction and Fetal Growth Restriction in Transgenic Mice.Int J Mol Sci. 2024 Feb 7;25(4):2040. doi: 10.3390/ijms25042040. Int J Mol Sci. 2024. PMID: 38396719 Free PMC article.
-
SARS-CoV-2 Infection in Late Pregnancy and Childbirth from the Perspective of Perinatal Pathology.J Dev Biol. 2023 Nov 16;11(4):42. doi: 10.3390/jdb11040042. J Dev Biol. 2023. PMID: 37987372 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous